Liquidia Technologies

Home

Site Map

COMPANY

Liquidia Technologies is developing highly precise particle-based vaccines and therapeutics for the prevention and treatment of human disease. Combining a deep understanding of particle-based drug development with breakthrough small molecule and biological therapeutics, Liquidia is engineering vaccines and therapies that have the potential to dramatically improve the quality of human life. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.
Learn more >

PRODUCT PLATFORM

Utilizing a novel platform known as PRINT® technology, Liquidia is designing highly specific carriers for delivery of small molecules and biological cargos. This breakthrough platform technology makes it possible for the first time to design vaccines and therapies with precise control of particle size, shape, and composition.
Learn more >

RECENT NEWS

December 13, 2011
Liquidia Technologies Announces Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine Details

November 24, 2011
To Advance Their Cause, Foundations Buy Stocks Details

November 7, 2011
Liquidia Technologies receives investment deal of the year award from Southeast Bio Details

November 2, 2011
NC Companies Succeed with Platform Technologies Details

October 18, 2011
Liquidia Founder to shocase PRINT® Technology at TEDMED Annual Conference Details